Suboxone is not being discontinued. The brand-name sublingual film and multiple generic versions remain FDA-approved and available in the United States. There is no entry for Suboxone on the FDA’s drug shortage or discontinuation list. However, several real-world changes, including insurance formulary shifts, pharmacy stocking issues, and the earlier discontinuation of Suboxone *tablets*, have created understandable confusion about whether the medication is going away.
What Actually Was Discontinued
The source of much of this confusion traces back to 2013, when the manufacturer Reckitt Benckiser (now Indivior) stopped distributing Suboxone sublingual tablets. The company publicly stated it was pulling the tablets for safety reasons, claiming the newer film version posed less risk of accidental exposure to children. The FDA investigated and determined the tablets were not withdrawn for reasons of safety or effectiveness. The agency moved the tablets to the “Discontinued Drug Product List” but kept the film version fully active.
This move was later scrutinized as a competitive strategy. The Federal Trade Commission charged that Reckitt employed a “product hopping” scheme, misrepresenting the film as safer to shift prescriptions away from tablets before cheaper generic tablets hit the market. Reckitt agreed to pay $50 million and its former subsidiary Indivior paid an additional $10 million to settle the antitrust charges. The brand-name Suboxone film, however, has remained on the market continuously since its introduction.
Why Your Pharmacy Might Not Have It
If you’ve had trouble filling a Suboxone prescription, you’re not alone, but the reason likely isn’t a discontinuation. Pharmacies face a unique set of pressures when it comes to stocking buprenorphine products. When demand rises, suppliers sometimes delay or pause shipments to pharmacies to avoid scrutiny from the Drug Enforcement Administration. Many pharmacies refuse to stock buprenorphine altogether out of concern that their orders will be flagged under the Controlled Substances Act.
These problems hit some communities harder than others. Independent pharmacies in Black and Latino neighborhoods are significantly less likely to carry buprenorphine and more likely to stop stocking it over time. In 73 rural counties heavily affected by the opioid crisis, fewer than 25% of pharmacies carried the medication, and another 25 counties had no pharmacy at all. So while the drug is manufactured and available at a national level, access at the local level can be genuinely difficult.
Insurance Has Shifted Toward Generics
Another reason people may believe Suboxone is disappearing: their insurance stopped covering the brand name. Multiple generic versions of buprenorphine/naloxone sublingual film are now available from manufacturers including Dr. Reddy’s Laboratories, Mylan, Alvogen, and Difgen Pharmaceuticals, with Camber Pharmaceuticals expected to enter the market in 2026. Medicare Part D plans rapidly replaced brand-name Suboxone with these generics once they became available, and many private insurers have done the same.
For most patients, the switch is seamless. Generics contain the same active ingredients at the same doses. But the transition isn’t trouble-free for everyone. In one study of 24 patients who were switched from brand-name Suboxone to a generic, 9 experienced withdrawal symptoms, cravings, needed a dosage adjustment, or had positive urine tests. Researchers have noted that patients forced to switch formulations may need additional monitoring to make sure the new version is working as well as the old one. If your pharmacy hands you a different-looking film than you’re used to, that’s almost certainly a generic substitution, not a sign that Suboxone has been pulled from the market.
Long-Acting Alternatives Are Growing
The treatment landscape for opioid use disorder has also expanded, which can contribute to the impression that daily films are being phased out. Sublocade, a once-monthly injection of buprenorphine, eliminates the need for daily dosing entirely. It can only be started in patients who have already been taking a daily buprenorphine product like Suboxone and tolerated it well. For people in stable recovery, the monthly injection reduces the burden of daily medication and lowers the risk of diversion.
These newer options are additions to the toolkit, not replacements. Daily sublingual films remain the most widely prescribed form of buprenorphine treatment, and nothing in current FDA guidance or manufacturer announcements suggests that will change. If your provider has recommended switching to an injectable, that’s a clinical decision about what works best for your recovery, not a reflection of Suboxone’s availability.
What to Do If You Can’t Find It
If you’re having trouble getting your prescription filled, the issue is almost certainly local supply or insurance coverage rather than a national discontinuation. Calling ahead to confirm a pharmacy stocks buprenorphine before bringing in your prescription can save time and frustration. Chain pharmacies with centralized ordering systems tend to have more reliable supply than independent pharmacies, though this varies by region. If your insurer has moved you to a generic and you’re experiencing new symptoms like cravings or withdrawal, let your prescriber know so your dose or formulation can be adjusted rather than assuming the medication is no longer available.